Congressional critics of pharmaceutical marketing practices launched another volley in their battle to curb industry influence on prescribers with the July 31 introduction of legislation that would create a federally-supported "academic detailing" program
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.
Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.
The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.
